Structure via PubChem · Public domain (PubChem)
paricalcitol
Sign in to saveAlso known as Zemplar®, 19-Nor-1alpha,25-dihydroxyvitamin D2
Paricalcitol (chemically it is 19-nor-1,25-(OH)2-vitamin D2. Marketed by Abbott Laboratories under the trade name Zemplar) is a drug used for the prevention and treatment of secondary hyperparathyroidism (excessive secretion of parathyroid hormone) associated with chronic kidney failure. It is an analog of 1,25-dihydroxyergocalciferol, the active form of vitamin D2 (ergocalciferol).
Chemical data
- Formula
- C27H44O3
- Molecular weight
- 416.6 g/mol
- IUPAC name
- trans-(1R,3R)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(E,2R,5S)-6-hydroxy-5,6-dimethylhept-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]cyclohexane-1,3-diol
- SMILES
- C[C@H](/C=C/[C@H](C)C(C)(C)O)[C@H]1CC[C@@H]\2[C@@]1(CCC/C2=C\C=C3C[C@H](C[C@@H](C3)O)O)C
- InChIKey
- BPKAHTKRCLCHEA-UBFJEZKGSA-N
- XLogP
- 5
- Polar surface area
- 60.7 Ų
- H-bond donors
- 3
- H-bond acceptors
- 3
- Formal charge
- 0
via PubChem
Drug data · ChEMBL
- Max clinical phase
- Approved
- Molecule type
- Small molecule
- First approval
- 1998
- Admin. routes
- oral, parenteral
- Indications
- chronic kidney disease, IGA glomerulonephritis, Proteinuria, secondary hyperparathyroidism
via ChEMBL · EBI
Research
852 papers- Paricalcitol and Extended-Release Calcifediol for Treatment of Secondary Hyperparathyroidism in Non-Dialysis Chronic Kidney Disease: Results From a Network Meta-Analysis.The Journal of clinical endocrinology and metabolism · 2023
- Paricalcitol plus hydroxychloroquine enhances gemcitabine activity and induces mesenchymal to epithelial transition in pancreatic ductal adenocarcinoma: A single cell RNA-seq analysis.Cancer letters · 2025
- Paricalcitol ameliorates diabetic nephropathy by promoting EETs and M2 macrophage polarization and inhibiting inflammation by regulating VDR/CYP2J2 axis.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2024
- Pembrolizumab ± paricalcitol in metastatic pancreatic cancer postmaximal cytoreduction.The oncologist · 2025
- Efficacy and safety of paricalcitol in patients undergoing hemodialysis: a meta-analysis.Drug design, development and therapy · 2019
via PubMed
Wikidata facts
- Subclass of
- sterol
- Mass
- 416.329045
- Manufacturer
- Pfizer
- Has use
- medication
Show 6 more facts
- medical condition treated
- hyperparathyroidism
- chemical formula
- C₂₇H₄₄O₃
- canonical SMILES
- CC(C=CC(C)C(C)(C)O)C1CCC2C1(CCCC2=CC=C3CC(CC(C3)O)O)C
- isomeric SMILES
- C[C@H](/C=C/[C@H](C)C(C)(C)O)[C@H]1CC[C@@H]\2[C@@]1(CCC/C2=C\C=C3C[C@H](C[C@@H](C3)O)O)C
- World Health Organisation international non-proprietary name
- paricalcitol
- physically interacts with
- vitamin D receptor
Sources (6)
via Wikidata · CC0
~5 min read
Encyclopedic overview
8 sectionsContents
- Medical uses
- Adverse effects
- Contraindications
- Interactions
- Overdose
- Mechanism of action
- Pharmacokinetics
- References
Paricalcitol (chemically it is 19-nor-1,25-(OH)2-vitamin D2. Marketed by Abbott Laboratories under the trade name Zemplar) is a drug used for the prevention and treatment of secondary hyperparathyroidism (excessive secretion of parathyroid hormone) associated with chronic kidney failure. It is an analog of 1,25-dihydroxyergocalciferol, the active form of vitamin D2 (ergocalciferol).
It was patented in 1989 and approved for medical use in 1998.
Excerpted from Wikipedia’s “paricalcitol” article, available under the CC BY-SA 4.0 licence.